Irrational Exubera-nce for Pfizer?
Investors cheered when, on Jan. 27, the U.S. Food & Drug Administration approved Pfizer's Exubera, the first inhaled insulin therapy to reach the market. The general consensus among analysts is that Exubera is likely to be a blockbuster.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.